NCT00049452View on ClinicalTrials.gov

Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 31, 2001

Study Completion Date

August 31, 2008

Conditions
Breast CancerOsteoporosis
Interventions
DRUG

zoledronic acid

Trial Locations (3)

10032

Herbert Irving Comprehensive Cancer Center at Columbia University, New York

06904

Carl and Dorothy Bennett Cancer Center at Stamford Hospital, Stamford

07652-2509

Valley Hospital - Paramus, Paramus

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Herbert Irving Comprehensive Cancer Center

OTHER

NCT00049452 - Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer | Biotech Hunter | Biotech Hunter